SLN360
SLN360-001
Phase 1 small_molecule completed
Quick answer
SLN360 for Hyperlipidemias is a Phase 1 program (small_molecule) at Silence Therapeutics plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Silence Therapeutics plc
- Indication
- Hyperlipidemias
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed